We maintain active research and development programs related to the characterization and validation of new translational research models and technologies that can reduce risk and drive further efficiencies in the drug discovery and development process. This is achieved by harnessing significant therapeutic domain expertise, robust study design and data analysis, and state of the art instrumentation and endpoints, coupled with our unique primate research resources. Our translational research is often conducted in collaboration with industry and academic partners to ensure we are leveraging the most innovative thinking and scientific resources available in terms of defining and addressing the most pressing unmet disease modeling needs. Present research and development programs include:
- Dry age-related macular degeneration (AMD)
- Chronic vascular leakage
- Congestive heart failure
Central Nervous System
- Alzheimer’s disease
- Metabolic syndrome
- Biomarkers of aging
Validated Efficacy Models
We maintain a rigorous scientific process related to characterization and validation of new models and associated drug discovery and development applications. Before a model can move from Research status to Screening status, a model must meet the following criteria:
- The clinically relevant disease pathology can be induced reproducibly with sufficient statistical confidence that a drug screening protocol can be designed and executed toward a specific discovery and development objective.
- The induced disease pathology can be modulated by therapeutic intervention using the current clinical standard of care and/or the known drug target is present in healthy and/or induced conditions and can be measured through clinically relevant endpoints and/or scientifically validated assays.
- Wet-age-related macular degeneration
- Retinal neovascularization
- Surgical Inflammation
- Optic Neuropathy
- Ocular Toxicology
- Ocular Pharmacokinetics
Central Nervous System
- Parkinson’s disease
- Spinal cord injury
- Behavior & Cognition
- Heart failure
- Diet-induced Obesity
- Metabolic Syndrome
- Adjuvant and Vaccine Development
Research Collaborations & Co-Development
RxGen routinely works with study sponsors to create and optimize translational models and to define and validate endpoints applicable to both preclinical and clinical study designs. We embrace a collaborative approach to new model development and pursue co-development opportunities that are enabled by our platform. Our ability to study a diverse population of mixed sex and ages, or a phenotypic subpopulation defined with respect to specific study aims, provides a unique and enabling path to developing and applying more clinically relevant models.
If you have a compelling strategy for an inducible disease and/or other screening model that might be amendable to validation and application in a clinically relevant test system, contact us at .